The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 3
Abstract
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Materials and Methods: Between July 2016 and September 2018, a total of 25 CHD patients treated with PrOD were enrolled. The patients with hepatitis C virus (HCV) genotype 1a were treated with PrOD plus ribavirin (RBV) (12 or 24 weeks according to whether or not they had compensated cirrhosis), while the patients with genotype 1b were treated with PrOD alone. Liver functions, renal functions, and HCV-RNA levels were measured at baseline, 4, 12, and if applicable, 24 weeks after the initiation of treatment as well as 4 and 12 weeks after therapy. Results: Nineteen patients received PrOD, while 6 received PrOD plus RBV treatment. Two patients failed to complete the treatment. Two patients with compensated cirrhosis were treated over 24 weeks, while others received 12 weeks. In 23 patients completed 12 weeks, all were HCV-RNA negative at the end of the treatment, and had sustained virologic response (SVR) after the 12 weeks of treatment. The most common side effects were pruritus and anaemia. Conclusion: The PrOD treatment resulted in a high rate of SVR in HCV-infected CHD.
Authors and Affiliations
Nilay Danış, Hüsnü Pullukçu, Tansu Yamazhan, Galip Ersöz, Nalan Ünal, Fulya Günşar, İlker Turan, Zeki Karasu, Ulus Salih Akarca
Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report
Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been repor...
Which is More Important and Insidious in Dialysis Patients? Occult Hepatitis B or Occult Hepatitis C?
Objectives: The aim of this study was to investigate the presence of occult hepatitis B infection (OBI) and Occult hepatitis C infection (OCI) in hemodialysis patients and to determine whether there is an activation in t...
Investigating Hepatitis C, D and HIV Prevalance in Cases with Positive Hepatitis B Virus Antigen in a Tertiary Hospital and Examining Anti-HDV Positive Cases
Objectives: Hepatitis B infection has a faster and more progressive course in the presence of hepatitis C virus (HCV), HDV and human immunodeficiency virus (HIV) infections. The aim of this study was to determine anti-HC...
Intravenous Drug Use Rates and Results of Direct-acting Antiviral Treatment in Prisoner Patients
Objectives: Intravenous drug use (IVDU) is more common in prisoner patients, and this is a global problem. Hepatitis C virus (HCV) infection is higher in prisoners than general population. In our study, we aimed to exami...
Relationship between Viral Load and Hepatic Histopathology in Patients with Chronic Hepatitis B
Objectives: It is not always possible to determine a clear relationship between the DNA level of hepatitis B virus (HBV) and histology. In this study, we aimed to determine the relationship between HBV-DNA level and live...